|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM123611407 |
| 003 |
DE-627 |
| 005 |
20231222201732.0 |
| 007 |
tu |
| 008 |
231222s2003 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0412.xml
|
| 035 |
|
|
|a (DE-627)NLM123611407
|
| 035 |
|
|
|a (NLM)12584049
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Clegg, Alison
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Chemokine receptor genotype and response to interleukin-2 therapy in HIV-1-infected individuals
|
| 264 |
|
1 |
|c 2003
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 26.03.2003
|
| 500 |
|
|
|a Date Revised 06.11.2019
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Interleukin-2 therapy is an immune-based treatment for HIV-1-infected individuals with declining CD4(+) T cell counts. Intravenous IL-2 produces an elevation of circulating CD4(+) T cells, but with a varying degree of effectiveness in individual patients. IL-2 is also known to increase the expression of chemokine receptors, coreceptors for HIV-1. Allelic variation in chemokine receptor genes can markedly affect the course of HIV disease; consequently, we analyzed CCR5 and CCR2B genotypes among a cohort of HIV-1-infected individuals that received IL-2 therapy. DNA was extracted from treated individuals and genotyping was performed using PCR followed by allele-specific detection or cleavage of the amplified product. Samples from 47 trial participants (25 CIV-IL-2 group; 22 placebo group) were analyzed for CCR5 and CCR2B genotype. We report that CCR5 Delta 32 heterozygous individuals had a greater CD4(+) T cell response to continuous intravenous IL-2 (CIV-IL-2) treatment than those homozygous for the wild-type allele (median = 427 vs 237 cells/mm(3); P = 0.03). This study highlights the importance of interactions between IL-2 and CCR5; at the clinical level, it argues for assessment of chemokine receptor genotype in IL-2 and perhaps other immune-based therapy trials
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a CCR2 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-2
|2 NLM
|
| 650 |
|
7 |
|a Receptors, CCR2
|2 NLM
|
| 650 |
|
7 |
|a Receptors, CCR5
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Chemokine
|2 NLM
|
| 700 |
1 |
|
|a Williamson, Peter
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Biti, Robyn
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cooper, David
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Emery, Sean
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Carr, Andrew
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Stewart, Graeme
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 106(2003), 1 vom: 01. Jan., Seite 36-40
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:106
|g year:2003
|g number:1
|g day:01
|g month:01
|g pages:36-40
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 106
|j 2003
|e 1
|b 01
|c 01
|h 36-40
|